239 Days: Oncopeptides' Myeloma Drug Pepaxto Comes Off Market Just Months After Accelerated Approval

 
• By Sue Sutter

Withdrawal announcement marks shortest interval ever from accelerated approval to market removal after OCEAN confirmatory trial showed an adverse overall survival trend and US FDA said a hypothesis-generating subgroup analysis would need to be borne out in another study.

Sinking ship
An adverse survival trend in a confirmatory trial sank Pepaxto's chances of remaining on the market • Source: Alamy

More from Drug Safety

More from Pink Sheet